Uptravi vs. Tyvaso

Uptravi (selexipag) and Tyvaso (treprostinil) are used to treat pulmonary arterial hypertension.

Uptravi and Tyvaso belong to different drug classes. Uptravi is a prostacyclin receptor agonist and Tyvaso is a vasodilator.

Side effects of Uptravi and Tyvaso that are similar include headache, diarrhea, jaw pain, nausea, muscle pain, and flushing (warmth, redness, or tingly feeling).

Side effects of Uptravi that are different from Tyvaso include vomiting, pain in extremities, joint pain, low levels of iron in the blood (anemia), decreased appetite, and rash.

Side effects of Tyvaso that are different from Uptravi include cough, sore throat, throat irritation or pain after use, dizziness, and bone pain.

Both Uptravi and Tyvaso may interact with gemfibrozil.

Uptravi may also interact with teriflunomide, deferasirox, and rifampin.

Tyvaso may also interact with delavirdine, nicardipine, pioglitazone, tolbutamide, antibiotics, antifungals, blood pressure medications, blood thinners, diuretics, medications to treat congestive heart failure, nonsteroidal anti-inflammatory drugs (NSAIDs), seizure medications, and sulfa drugs.

Common side effects of Uptravi include:

Side effects of Uptravi include:

• headache,
• diarrhea,
• jaw pain,
• nausea,
• muscle pain,
• vomiting,
• pain in extremities,
• flushing (warmth, redness, or tingly feeling),
• joint pain,
• low levels of iron in the blood (anemia),
• decreased appetite, or
• rash

Common side effects of Tyvaso include:

• cough
• headache
• sore throat
• throat irritation or pain after use
• nausea
• flushing
• dizziness
• diarrhea
• jaw/muscle/bone pain
• flushing (warmth, redness, or tingling)

Fainting is another common side effect of Tyvaso. If fainting occurs after taking Tyvaso, get medical help right away.

Uptravi (selexipag) is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Tyvaso (treprostinil) Inhalation Solution is a vasodilator used to treat pulmonary arterial hypertension (PAH). Tyvaso improves your ability to exercise and prevents your condition from getting worse.

Uptravi may interact with strong inhibitors of CYP2C8 (e.g., gemfibrozil). Tell your doctor all medications and supplements you use.

Tyvaso may interact with gemfibrozil, delavirdine, nicardipine, pioglitazone, tolbutamide, antibiotics, antifungals, blood pressure medications, blood thinners, diuretics, medications to treat congestive heart failure, NSAIDs (non-steroidal anti-inflammatory drugs), seizure medications, or sulfa drugs. Tell your doctor all medications and supplements you use.

The starting dose of Uptravi is 200 mcg twice daily. Increase the dose of Uptravi by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily.

The initial adult dosage of Tyvaso therapy should begin with 3 breaths of Tyvaso (18 mcg of treprostinil), per treatment session, 4 times daily. If 3 breaths are not tolerated, reduce to 1 or 2 breaths and subsequently increase to 3 breaths, as tolerated.